Appointment of Non Executive Director and Chairman
Released
Released
Announcement PDF
ASX / MEDIA ANNOUNCEMENT
INVION APPOINTS MR THIAN CHEW AS DIRECTOR AND CHAIRMAN
Brisbane, Australia and Delaware, United States, 1 December 2017: Invion Limited (ASX: IVX) is pleased
to announce the appointment of Mr Thian Chew as Non-Executive Director and Chairman of the Board
of Directors.
Invion Managing Director and Chief Executive Officer Dr Greg Collier said: “We are delighted to
welcome Thian to the Board. Following yesterday’s Annual General Meeting which saw Invion
shareholders approving all resolutions relating to the licence to commercialise Photosoft™ for the
treatment of cancers, we are very positive about the Company’s future and look forward to working
together to progress clinical and commercial development plans.”
Mr Chew has over 25 years’ experience in investing, finance and transforming business operations. He
is Managing Partner at Polar Ventures, a private investment and consulting firm that provides capital,
strategic and operating solutions, focusing on small to mid-sized enterprises in Asia.
Mr Chew was previously an Executive Director at Goldman Sachs (Hong Kong and New York)
responsible for the firm’s proprietary investments including growth capital, private equity and special
situations in both private and public companies.
Prior to this, he was a Consultant Project Manager to Morgan Stanley, New York. Mr Chew also held a
number of positions in KPMG across Asia Pacific including Director at KPMG Consulting (Singapore and
Sydney) where he led several large scale operational restructuring, post-merger integration,
transformation, and business performance improvement programs.
As a Senior Manager at KPMG
(Taipei and Melbourne), he led several business process re-engineering initiatives, and also performed
financial and information technology audit, risk and assurance engagements across multiple industries.
Mr Chew holds an MBA from the Wharton School (Palmer Scholar), MA from the Lauder Institute,
University of Pennsylvania, and a Bachelor of Information Systems from Monash University. Mr Chew is
an Adjunct Professor at HKUST’s MBA program and previously qualified as a chartered accountant.
Dr Collier returns to MD and CEO role
Dr Greg Collier, who has acted as Interim Executive Chair since February 2016, returns to his role as
Managing Director and CEO, effective immediately. The material terms of Dr Collier’s CEO contract
have not changed other than, as proposed by Dr Collier and agreed by the Board, effective
1 December 2017, Dr Collier will be engaged at a 2/3 rate, with this being regularly reviewed.
About Photosoft™
Photosoft™ is a new generation photosensitiser derived from chlorophyll which is hypothesised to
identify and selectively accumulate within solid cancerous tumour tissues. Photosoft™ is activated at
multiple light sensitivity ranges across a broad spectrum, and therefore has potential to be targeted to
both surface and deep seated tumours.
Invion Limited ABN 76 094 730 417
GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com
ASX / MEDIA ANNOUNCEMENT
Invion has an agreement with The Cho Group to conduct clinical development of Photosoft™ globally,
leveraging the Company’s expertise. The Cho Group will provide non-dilutive funding to Invion for R&D
and clinical trials as part of a global development strategy for the asset. Invion has also been granted
exclusivity in Australia and New Zealand to commercialise and distribute Photosoft™ for the treatment
of cancers.
-----FOR MORE INFORMATION CONTACT: Managing Director & CEO, Dr Greg Collier. P: 07 3295 0500
investor@inviongroup.com
Invion Limited ABN 76 094 730 417
GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com
Share your feedback
Discover